Morning After Pill Shortage: What Providers and Prescribers Need to Know in 2026

While there is no FDA-declared national shortage of emergency contraceptives in 2026, your patients are still asking about access to Plan B and ella—and many are encountering real barriers. Understanding the current supply landscape, prescribing nuances, and how to guide patients efficiently can make a significant difference in their outcomes. This clinical overview is designed for OB-GYNs, primary care providers, nurse practitioners, physician assistants, and any clinician who counsels patients on reproductive health.

Current Availability Status: No National Shortage, But Real Access Gaps

As of 2026, neither levonorgestrel (Plan B) nor ulipristal acetate (ella) appears on the FDA Drug Shortage Database. Both are produced by multiple manufacturers. However, several structural factors continue to create access gaps for patients:

• Demand surges: Political events related to reproductive rights have repeatedly triggered demand surges that cause temporary regional stock depletion.
• Pharmacy refusals: Conscience clause laws in multiple states permit pharmacists to decline dispensing emergency contraception. This disproportionately affects patients in states with restrictive reproductive health laws.
• Prescription requirement for ella: Ulipristal acetate (ella) requires a prescription and is often not stocked at smaller independent pharmacies, creating disproportionate access barriers for patients who need it most.
• Geographic disparities: Rural pharmacy deserts mean patients may face significant travel time to reach a stocked pharmacy, which is critical given the time-sensitive nature of emergency contraception.

Clinical Review: Selecting the Right Emergency Contraceptive

For most patients presenting within 72 hours of unprotected intercourse, OTC levonorgestrel (Plan B or generic) is appropriate, accessible, and affordable. For patients in the following situations, a different approach should be considered:

• Body weight >165 lbs: Recommend ella (ulipristal acetate) as the preferred pill option, or copper IUD if the patient is open to an IUD. Evidence suggests reduced levonorgestrel efficacy at higher BMIs, though current FDA labeling does not specify a weight cutoff.
• 72–120 hours post-coitus: Ella is the preferred pill option. The copper IUD remains viable and is more effective. Levonorgestrel is not well-studied for efficacy beyond 72 hours.
• Interacting medications: Patients on CYP3A4 inducers (rifampin, carbamazepine, phenytoin, topiramate, oxcarbazepine, barbiturates, St. John's wort) should be counseled that both levonorgestrel and ella may have reduced efficacy. The copper IUD is the appropriate recommendation for these patients.
• Ongoing contraception desired: The copper IUD provides emergency contraception and up to 10 years of ongoing highly effective contraception. This is an opportunity to offer long-term contraceptive counseling.

Key Drug Interactions for Emergency Contraceptives

Providers should screen for the following interactions before recommending pill-based emergency contraception:

• Rifampin (TB treatment): Significantly reduces levonorgestrel and ella efficacy
• Carbamazepine, phenytoin, topiramate, oxcarbazepine, felbamate (anticonvulsants): Reduce ella efficacy
• Barbiturates (phenobarbital, primidone): Reduce ella efficacy
• Griseofulvin: Reduces both Plan B and ella efficacy
• St. John's wort (herbal supplement): Reduces levonorgestrel efficacy
• Efavirenz (HIV antiretroviral): Reduces Plan B efficacy; copper IUD preferred
• Hormonal birth control and ella: Progesterone-containing contraceptives reduce ella's efficacy. Counsel patients to wait 5 days after ella before restarting hormonal contraceptives.

Advance Prescription Strategy for Ella

Many clinical guidelines support writing advance prescriptions for ella so patients can keep it at home before they need it. Studies show that having emergency contraception on hand is associated with earlier use and better outcomes, without increasing rates of unprotected sex. Consider offering ella advance prescriptions routinely during annual well-woman visits and contraceptive counseling appointments.

Counseling Patients on Accessing Emergency Contraception Quickly

Patient counseling on emergency contraception should include:

1. Take Plan B or ella as soon as possible after unprotected sex—efficacy declines with each passing hour.
2. If vomiting occurs within 2 hours (Plan B) or 3 hours (ella) of taking the dose, repeat the dose and contact their provider.
3. After ella, use barrier contraception until the next menstrual period. Wait at least 5 days before restarting hormonal birth control.
4. If periods are more than 1 week late after EC use, take a home pregnancy test.
5. Severe lower abdominal pain 3–5 weeks after EC use should prompt evaluation for ectopic pregnancy.

How medfinder Helps Your Patients

For patients who need to locate emergency contraception quickly after leaving your office, medfinder for providers is a resource worth sharing. medfinder calls pharmacies near a patient's location to identify which ones have the requested medication in stock. For time-sensitive situations like emergency contraception, this service helps patients act within their window without wasting time on hold.

See also: How to help your patients find the morning after pill in stock.